CN118660904A - 具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体 - Google Patents

具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体 Download PDF

Info

Publication number
CN118660904A
CN118660904A CN202280091299.9A CN202280091299A CN118660904A CN 118660904 A CN118660904 A CN 118660904A CN 202280091299 A CN202280091299 A CN 202280091299A CN 118660904 A CN118660904 A CN 118660904A
Authority
CN
China
Prior art keywords
amino acid
cxcr3
cxcr3 ligand
ligand
parent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091299.9A
Other languages
English (en)
Chinese (zh)
Inventor
山本阳平
加门北斗
渡边美穗
筒井遥香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN118660904A publication Critical patent/CN118660904A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280091299.9A 2021-12-23 2022-12-22 具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体 Pending CN118660904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-209975 2021-12-23
JP2021209975 2021-12-23
PCT/JP2022/047366 WO2023120643A1 (ja) 2021-12-23 2022-12-22 Ｃｘｃｒ３発現細胞遊走活性が増強したｃｘｃｒ３リガンド。

Publications (1)

Publication Number Publication Date
CN118660904A true CN118660904A (zh) 2024-09-17

Family

ID=86902738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280091299.9A Pending CN118660904A (zh) 2021-12-23 2022-12-22 具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体

Country Status (5)

Country Link
US (1) US20250073307A1 (https=)
EP (1) EP4455158A4 (https=)
JP (1) JPWO2023120643A1 (https=)
CN (1) CN118660904A (https=)
WO (1) WO2023120643A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003082335A1 (ja) * 2002-04-03 2005-07-28 住友製薬株式会社 新規血糖調節薬及びそのスクリーニング方法
US20090131312A1 (en) * 2005-05-18 2009-05-21 Lawrence Blatt Non-natural chemokine receptor ligands and methods of use thereof
WO2018097308A1 (ja) 2016-11-28 2018-05-31 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
CN111836828B (zh) 2017-11-28 2024-12-20 中外制药株式会社 包括抗原结合结构域和运送部分的多肽
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
US20220017585A1 (en) * 2018-12-04 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Cxcr3 ligand
EP4021927A1 (en) 2019-08-29 2022-07-06 Antagonis Biotherapeutics GmbH T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity

Also Published As

Publication number Publication date
WO2023120643A1 (ja) 2023-06-29
EP4455158A4 (en) 2026-04-15
EP4455158A1 (en) 2024-10-30
JPWO2023120643A1 (https=) 2023-06-29
US20250073307A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
KR102675219B1 (ko) Ｓｉｒｐ-알파 변이체 구성체 및 이의 용도
KR20230054671A (ko) 활성화 가능한 치료제와 관련된 조성물 및 방법
EP3088517A1 (en) Human anti-il-33 neutralizing monoclonal antibody
KR102268830B1 (ko) Kv1.3 길항제 및 사용 방법
EP3426689A1 (en) Inducible binding proteins and methods of use
KR20170068553A (ko) 인터류킨-15 조성물 및 이의 용도
KR20160007604A (ko) 이중특이성 작제물 및 다양한 질병의 치료에서의 이의 용도
JPH07509613A (ja) インターロイキン−１０（ｉｌ−１０）のための哺乳類レセプター
KR101243951B1 (ko) 가용성 종양 괴사 인자 수용체 돌연변이
JP7438975B2 (ja) Ｃｘｃｒ３リガンド
US12497434B2 (en) IL-37 fusion proteins and uses thereof
JP5581214B2 (ja) 改善された結合活性をもつ可溶性ｇｐ１３０変異蛋白質
Hiraoka et al. Ligand binding domain of granulocyte colony-stimulating factor receptor.
CA3233644A1 (en) Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
CN118660904A (zh) 具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体
HK40108361A (zh) 具有增强的表达cxcr3的细胞迁移的活性的cxcr3配体
HK40068945A (en) Il-37 fusion proteins and uses thereof
JP2009513124A (ja) 新規ｃｘｃケモカインアンタゴニスト
CN121736105A (zh) 抗ccr8抗体及其应用
IL324787A (en) Il10 inverted monomers
CN116836259A (zh) 一种牛IgG Fc受体boFcγRII的线性配体结合表位
HK1244016B (zh) FC融合高亲和力IGE受体α链

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108361

Country of ref document: HK